Pulmonary Microbiota and Lung Cancer

This study systematically analyzes the research landscape of lung cancer and pulmonary microbiota from 2015 to 2024 using bibliometric methods. Data from the Web of Science Core Collection were examined to identify key contributors, research hotspots, and evolving trends. Results revealed a significant shift in focus from infections and inflammation to immunotherapy and microbial biomarkers, reflecting a growing emphasis on clinical translation. Major contributors, including China and the United States, along with leading journals, have driven progress in this interdisciplinary field, highlighting the role of microbial dysbiosis in tumor development and immune modulation.The findings underscore the potential of pulmonary microbiota as diagnostic tools and therapeutic targets, particularly in enhancing immunotherapy outcomes. This study provides a comprehensive overview of the field, offering valuable insights into its current status and future directions, and lays a foundation for further exploration in personalized medicine and multidisciplinary collaborations.